Faculty Bibliography

A novel functional additive model is proposed, which is uniquely modified and constrained to model nonlinear interactions between a treatment indicator and a potentially large number of functional and/or scalar pretreatment covariates. The primary motivation for this approach is to optimize individualized treatment rules based on data from a randomized clinical trial. We generalize functional additive regression models by incorporating treatment-specific components into additive effect components. A structural constraint is imposed on the treatment-specific components in order to provide a class of additive models with main effects and interaction effects that are orthogonal to each other. If primary interest is in the interaction between treatment and the covariates, as is generally the case when optimizing individualized treatment rules, we can thereby circumvent the need to estimate the main effects of the covariates, obviating the need to specify their form and thus avoiding the issue of model misspecification. The methods are illustrated with data from a depression clinical trial with electroencephalogram functional data as patients' pretreatment covariates.

Sparse additive modeling is a class of effective methods for performing high-dimensional nonparametric regression. This article develops a sparse additive model focused on estimation of treatment effect modification with simultaneous treatment effect-modifier selection. We propose a version of the sparse additive model uniquely constrained to estimate the interaction effects between treatment and pretreatment covariates, while leaving the main effects of the pretreatment covariates unspecified. The proposed regression model can effectively identify treatment effect-modifiers that exhibit possibly nonlinear interactions with the treatment variable that are relevant for making optimal treatment decisions. A set of simulation experiments and an application to a dataset from a randomized clinical trial are presented to demonstrate the method.

We consider a logistic regression model for a binary response where part of its covariates are subject-specific random intercepts and slopes from a large number of longitudinal covariates. These random effect covariates must be estimated from the observed data, and therefore, the model essentially involves errors in covariates. Because of high dimension and high correlation of the random effects, we employ longitudinal principal component analysis to reduce the total number of random effects to some manageable number of random effects. To deal with errors in covariates, we extend the conditional-score equation approach to this moderate dimensional logistic regression model with random effect covariates. To reliably solve the conditional-score equations in moderate/high dimension, we apply a majorization on the first derivative of the conditional-score functions and a penalized estimation by the smoothly clipped absolute deviation. The method was evaluated through a set of simulation studies and applied to a data set with longitudinal cortical thickness of 68 regions of interest to identify biomarkers that are related to dementia transition.

This paper presents a Bayesian reformulation of covariate-assisted principal regression for covariance matrix outcomes to identify low-dimensional components in the covariance associated with covariates. By introducing a geometric approach to the covariance matrices and leveraging Euclidean geometry, we estimate dimension reduction parameters and model covariance heterogeneity based on covariates. This method enables joint estimation and uncertainty quantification of relevant model parameters associated with heteroscedasticity. We demonstrate our approach through simulation studies and apply it to analyze associations between covariates and brain functional connectivity using data from the Human Connectome Project.

Widespread hyperalgesia, characterized by pain sensitivity beyond the primary pain site, is a common yet under-characterized feature across chronic pain conditions, including chronic pancreatitis (CP). In this exploratory study, we identified a candidate neural biosignature of widespread hyperalgesia using high-density electroencephalography (EEG) in patients with chronic low back pain (cLBP). Specifically, stimulus-evoked delta, theta, and alpha oscillatory activity in the bilateral medial orbitofrontal cortex (mOFC) differentiated cLBP patients with widespread hyperalgesia from healthy controls. To examine cross-condition generalizability and advance predictive biomarker development for CP, we applied this mOFC-derived EEG biosignature to an independent cohort of patients with CP. The biosignature distinguished CP patients with widespread hyperalgesia and predicted individual treatment responses to peripherally targeted endoscopic therapy. These preliminary findings provide early support for a shared cortical signature of central sensitization across pain conditions and offer translational potential for developing EEG-based predictive tools for treatment response in CP.

Stepped wedge cluster randomized trials (SWCRTs) often face challenges related to potential confounding by time. Traditional frequentist methods may not provide adequate coverage of an intervention's true effect using confidence intervals, whereas Bayesian approaches show potential for better coverage of intervention effects. However, Bayesian methods remain underexplored in the context of SWCRTs. To bridge this gap, we propose two innovative Bayesian hierarchical penalized spline models. Our first model accommodates large numbers of clusters and time periods, focusing on immediate intervention effects. To evaluate this approach, we compared this model to traditional frequentist methods. We then extend our approach to account for time-varying intervention effects, conducting a comprehensive comparison with an existing Bayesian monotone effect curve model and alternative frequentist methods. The proposed models were applied in the Primary Palliative Care for Emergency Medicine stepped wedge trial to evaluate the effectiveness of the intervention. Through extensive simulations and real-world application, we demonstrate the robustness of our proposed Bayesian models. Notably, the Bayesian immediate effect model consistently achieves the nominal coverage probability, providing more reliable interval estimations while maintaining high estimation accuracy. Furthermore, our proposed Bayesian time-varying effect model represents a significant advancement over the existing Bayesian monotone effect curve model, offering improved accuracy and reliability in estimation while also achieving higher coverage probability than alternative frequentist methods. To the best of our knowledge, this marks the first development of Bayesian hierarchical spline modeling for SWCRTs. Our proposed models offer promising tools for researchers and practitioners, enabling more precise evaluation of intervention impacts.

This paper presents a Bayesian regression model relating scalar outcomes to brain functional connectivity represented as symmetric positive definite (SPD) matrices. Unlike many proposals that simply vectorize the matrix-valued connectivity predictors, thereby ignoring their geometric structure, the method presented here respects the Riemannian geometry of SPD matrices by using a tangent space modeling. Dimension reduction is performed in the tangent space, relating the resulting low-dimensional representations to the responses. The dimension reduction matrix is learned in a supervised manner with a sparsity-inducing prior imposed on a Stiefel manifold to prevent overfitting. Our method yields a parsimonious regression model that allows uncertainty quantification of all model parameters and identification of key brain regions that predict the outcomes. We demonstrate the performance of our approach in simulation settings and through a case study to predict Picture Vocabulary scores using data from the Human Connectome Project.

BACKGROUND:Precision medicine has led to the development of targeted treatment strategies tailored to individual patients based on their characteristics and disease manifestations. Although precision medicine often focuses on a single health outcome for individualized treatment decision rules (ITRs), relying only on a single outcome rather than all available outcomes information leads to suboptimal data usage when developing optimal ITRs. METHODS:To address this limitation, we propose a Bayesian multivariate hierarchical model that leverages the wealth of correlated health outcomes collected in clinical trials. The approach jointly models mixed types of correlated outcomes, facilitating the "borrowing of information" across the multivariate outcomes, and results in a more accurate estimation of heterogeneous treatment effects compared to using single regression models for each outcome. We develop a treatment benefit index, which quantifies the relative benefit of the experimental treatment over the control treatment, based on the proposed multivariate outcome model. RESULTS:We demonstrate the strengths of the proposed approach through extensive simulations and an application to an international Coronavirus Disease 2019 (COVID-19) treatment trial. Simulation results indicate that the proposed method reduces the occurrence of erroneous treatment decisions compared to a single regression model for a single health outcome. Additionally, the sensitivity analyses demonstrate the robustness of the model across various study scenarios. Application of the method to the COVID-19 trial exhibits improvements in estimating the individual-level treatment efficacy (indicated by narrower credible intervals for odds ratios) and optimal ITRs. CONCLUSION/CONCLUSIONS:The study jointly models mixed types of outcomes in the context of developing ITRs. By considering multiple health outcomes, the proposed approach can advance the development of more effective and reliable personalized treatment.

BACKGROUND:There is a need to understand the relationship between COVID-19 Convalescent Plasma (CCP) anti-SARS-CoV-2 IgG levels and clinical outcomes to optimize CCP use. This study aims to evaluate the relationship between recipient baseline clinical status, clinical outcomes, and CCP antibody levels. METHODS:The study analyzed data from the COMPILE study, a meta-analysis of pooled individual patient data from 8 randomized clinical trials (RCTs) assessing the efficacy of CCP vs. control, in adults hospitalized for COVID-19 who were not receiving mechanical ventilation at randomization. SARS-CoV-2 IgG levels, referred to as 'dose' of CCP treatment, were retrospectively measured in donor sera or the administered CCP, semi-quantitatively using the VITROS Anti-SARS-CoV-2 IgG chemiluminescent immunoassay (Ortho-Clinical Diagnostics) with a signal-to-cutoff ratio (S/Co). The association between CCP dose and outcomes was investigated, treating dose as either continuous or categorized (higher vs. lower vs. control), stratified by recipient oxygen supplementation status at presentation. RESULTS:A total of 1714 participants were included in the study, 1138 control- and 576 CCP-treated patients for whom donor CCP anti-SARS-CoV2 antibody levels were available from the COMPILE study. For participants not receiving oxygen supplementation at baseline, higher-dose CCP (/control) was associated with a reduced risk of ventilation or death at day 14 (OR = 0.19, 95% CrI: [0.02, 1.70], posterior probability Pr(OR < 1) = 0.93) and day 28 mortality (OR = 0.27 [0.02, 2.53], Pr(OR < 1) = 0.87), compared to lower-dose CCP (/control) (ventilation or death at day 14 OR = 0.79 [0.07, 6.87], Pr(OR < 1) = 0.58; and day 28 mortality OR = 1.11 [0.10, 10.49], Pr(OR < 1) = 0.46), exhibiting a consistently positive CCP dose effect on clinical outcomes. For participants receiving oxygen at baseline, the dose-outcome relationship was less clear, although a potential benefit for day 28 mortality was observed with higher-dose CCP (/control) (OR = 0.66 [0.36, 1.13], Pr(OR < 1) = 0.93) compared to lower-dose CCP (/control) (OR = 1.14 [0.73, 1.78], Pr(OR < 1) = 0.28). CONCLUSION/CONCLUSIONS:Higher-dose CCP is associated with its effectiveness in patients not initially receiving oxygen supplementation, however, further research is needed to understand the interplay between CCP anti-SARS-CoV-2 IgG levels and clinical outcome in COVID-19 patients initially receiving oxygen supplementation.